白三烯受体拮抗剂普鲁司特治疗支气管哮喘

Leukotriene Recipient Antagonist Pranlukast Capsule Treat Bronchial Asthma

目的 :评价国产普鲁司特胶囊治疗支气管哮喘的临床疗效及其安全性。方法 :观察 112例支气管哮喘患者用药前、后哮喘自觉症状、肺功能指标、实验室指标及不良反应。结果 :患者治疗后第 1、2、3、4周的平均晨间PEF值、平均夜间PEF值较治疗前均有显著性改变 (P <0 .0 0 1)。治疗后第 2、4周FEV1值均较治疗前有显著性改善 (P <0 .0 0 0 1)。治疗 4周后 ,平均日间、夜间哮喘症状评分均减少明显 ,日间、夜间无症状天数的百分数增加明显。全天无症状天数的百分数增加、日间、夜间患者使用喘乐宁气雾剂喷数减少 ;治疗期间全天未用喘乐宁气雾剂天数的百分数增加。共 9例患者发生药物不良反应 ,发生率为 8.0 4% ;不良反应主要为胃肠道反应 ,反应均较轻微 ,不影响研究用药的完成。结论 :国产普鲁司特胶囊能改善支气管哮喘患者的肺功能、减轻哮喘症状 ,不良反应轻微 ,具有良好的临床疗效及安全性。

Objective: To assess the efficacy and safety of pranlukast on asthma patients. Methods: To investigate the asthmatic symptoms,pulmonary function,laboratory measurement and adverse effects in 112 patients after using study drug. Results: The average PEF in the morning and night improved significant after 1,2,3,4 weeks( P <0.001);FEV1 improved significant in these patients after 2,4 weeks ( P <0.001);average asthmatic symptoms score in the morning and night decreased significant after 4 weeks, the percent of symptomless days in the morning and night increase significant in these patients, the percent of symptomless all-days increase in these patients. The puff number of using ventolin decreased in the morning and night in these patients,the percent of days of no using ventolin all-days increased in these patients.9 patients had drug adverse effects, incidence was 8.04%. Adverse effects were gastrointestinal tract response mainly, these response were light, did not have effect on the study. Conclusion: Pranlukast could improve the pulmonary function and symptoms in asthma patients, adverse effect is light, pranlukast posses satisfactory clinic effect and safety.